NCT03292640View on ClinicalTrials.gov

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

PHASE3CompletedINTERVENTIONAL
Enrollment

547

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

May 14, 2018

Study Completion Date

May 14, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

DFD-03 (0.1% tazarotene) Lotion

DFD-03 Lotion (0.1% tazarotene) - twice daily application

DRUG

DFD-03 (0% tazarotene) Lotion (Placebo)

DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application

Trial Locations (1)

94538

Center for Dermatology Clinical Research Inc., Fremont

Sponsors
All Listed Sponsors
lead

Dr. Reddy's Laboratories Limited

INDUSTRY